Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 9/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8404122 | 0.94 | TNK2 (0.51) | TNK2FGFR2 | |
| SCHEMBL12648398 | 0.92 | TNK2 (0.45) | TNK2FGFR1ALDH1A1LMNARAF1 | |
| SCHEMBL8399178 | 0.88 | TNK2 (0.43) | TNK2RAF1SRCBTKKMT2A | |
| SCHEMBL8408291 | 0.87 | TNK2 (0.39) | TNK2LMNARAF1SRCFGFR2 | |
| SCHEMBL8404277 | 0.85 | TNK2 (0.41) | TNK2RAF1SRCFGFR2BTK | |
| SCHEMBL8404266 | 0.85 | TNK2 (0.40) | TNK2FGFR1ALDH1A1USP2LMNA | |
| SCHEMBL10242109 | 0.85 | TNK2 (0.39) | TNK2RAF1SRCFGFR2BTK | |
| SCHEMBL10242104 | 0.82 | TNK2 (0.42) | TNK2FGFR1RAF1SRCFGFR2 | |
| SCHEMBL8402327 | 0.82 | FGFR2 (0.52) | TNK2FGFR1FGFR2 | |
| SCHEMBL10241497 | 0.82 | RAF1 (0.47) | TNK2RAF1SRCBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090274698-A1 | Combination anti-cancer therapy | OSI PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274698-A1 | Combination anti-cancer therapy | MTOR, RICTOR, AKT1 | TNK2 144/4885FGFR1 363/4885ALDH1A1 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.